Changes in the management of Abivax
The French Abivax SA has had a new CEO since the beginning of May. Marc de Garidel took over the position and became interim chairman of the supervisory board.
Marc de Garidel has held various CEO positions over the past twelve years. most recently as CEO of CinCor Pharma. The company was sold to AstraZeneca in February. Before that, he was CEO of Corvidia Therapeutics since 2018, which was acquired by Novo Nordisk in August 2020. Other stints included Ipsen (2010-2016). He is still chairman of the board there, Amgen and Eli Lilly. Marc has a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, has a masters in international management (MIM) from Thunderbird Global School Management and an executive MBA from Harvard Business School.
In mid-April, Michael Ferguson started as the new Chief Commercial Officer at Abivax. Corinna zur Bonsen-Thomas stepped down as chair of the supervisory board, but remains a member of the board. While Prof. Dr. Hartmut J. Ehrlich, CEO of Abivax since its foundation, will retire from the company’s management. However, he will continue to be available as a strategic advisor.
Resalis/Vimeo
AstraZeneca
Astoriom